Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

2-iminobiotin - Neurophyxia

Drug Profile

2-iminobiotin - Neurophyxia

Alternative Names: 2-IB; 2-Iminobiotin; Neufix

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurophyxia
  • Developer Neurophyxia; University Medical Center Utrecht
  • Class Imidazoles; Neuroprotectants; Pentanoic acids; Small molecules
  • Mechanism of Action Nitric oxide synthase type I inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Asphyxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asphyxia

Most Recent Events

  • 03 Feb 2020 Phase II development is still ongoing for 2-iminobiotin for Asphyxia (Neurophyxia pipeline, February 2020)
  • 28 Sep 2017 University Medical Centre Utrecht and Neurophyxia completes a phase II trial in Asphyxia (In infants) in Netherlands (IV), before September 2017 (EudraCT2014-004265-25)
  • 23 May 2017 Neurophyxia terminates a phase II trial in Asphyxia (In neonates) because recruitment too slow and site decided to use hypothermia (exclusion criteria) in Turkey and Lithuania (IV) (NCT01626924)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top